Bio-Techne (TECH) Non Operating Investment Income (2014 - 2023)
Bio-Techne (TECH) posted quarterly Non Operating Investment Income of $283000.0 for Q3 2023, down 99.43% year-over-year from $49.8 million in Q3 2022, and up 141.56% quarter-over-quarter from -$681000.0 in Q2 2023.
Powered by 
Analysis
Bio-Techne (TECH) Non Operating Investment Income (2014 - 2023) Analysis & Trends
Bio-Techne's Non Operating Investment Income history runs 3 years deep, the most recent figure standing at $283000.0 for Q3 2023.
- In Q3 2023, Non Operating Investment Income fell 99.43% year-over-year to $283000.0; the TTM figure through Jun 2024 stood at $283000.0 (down 99.43% YoY), while the FY2024 annual figure was $283000.0, down 99.43% from the prior year.
- Non Operating Investment Income for Q3 2023 stood at $283000.0, up from -$681000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $49.8 million in Q3 2022, with the low at -$681000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.07 Bn | 132.22 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.71 Bn | 58.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.51 Bn | 52.37 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.11 Bn | 35.01 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.41 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - | - |
| 9 | Insmed | 27.64 Bn | 26.48 Bn | 358.27 Mn | - |
| 10 | Bio-Techne | 11.30 Bn | 11.03 Bn | 211.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 283,000.00 |
| Jun 30, 2023 | -681,000.00 |
| Mar 31, 2023 | 314,000.00 |
| Dec 31, 2022 | -74,000.00 |
| Sep 30, 2022 | 49.77 Mn |
| Dec 31, 2014 | 8.30 Mn |